Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results
Quoin Pharmaceuticals, Ltd. - American Depositary Shares (QNRX)
Company Research
Source: GlobeNewswire
– Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D – Sally Lawlor Appointed CFO to Support Commercialization and Financial Operations – Orphan Drug Designation Awarded by FDA to QRX003 for Netherton Syndrome – Pediatric Netherton Clinical Program Expanded Based on Positive Long-Term Safety and Efficacy Data – QRX003 Pivotal Studies to Commence Enrollment in Q4 2025 – NETHERTON NOW Awareness Campaign Videos Achieve Over 1.5 Million Views in 6 Months Since Launch. – Positive Peeling Skin Data and Study Expansion Plans Released ASHBURN, Va., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases provided a corporate update today and announced its financial results for the third quarter ended September 30, 2025. “The third quarter of 2025 has been a period of significant momentum and stra
Show less
Read more
Impact Snapshot
Event Time:
QNRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QNRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QNRX alerts
High impacting Quoin Pharmaceuticals, Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
QNRX
News
- Quoin Pharmaceuticals (NASDAQ:QNRX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Quoin Pharmaceuticals (NASDAQ:QNRX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies [Yahoo! Finance]Yahoo! Finance
- Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery TechnologiesGlobeNewswire
- Quoin Pharmaceuticals (NASDAQ:QNRX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
QNRX
Sec Filings
- 12/16/25 - Form SCHEDULE
- 12/15/25 - Form SCHEDULE
- 12/11/25 - Form SCHEDULE
- QNRX's page on the SEC website